Literature DB >> 6331546

Interaction of plasma lipoproteins with human platelets.

L K Curtiss, E F Plow.   

Abstract

Human plasma low density lipoproteins (LDL) and high density lipoproteins (HDL) were radioiodinated and their interaction with washed human platelets was assessed. Both ligands were bound by the platelet at 37 degrees C, and an apparent equilibrium was attained within two hours. Minimal binding was observed at 22 degrees C or 4 degrees C. The specificity of these interactions was indicated by the observations that: (a) labeled and nonlabeled lipoproteins interacted with the platelet with the same apparent affinity; (b) nonlabeled lipoproteins inhibited binding, whereas unrelated plasma proteins did not; and (c) the platelet-bound ligands exhibited the appropriate apoprotein chain compositions when analyzed by polyacrylamide gel electrophoresis. Binding of HDL and LDL was found to be independent of the state of platelet activation and did not require divalent ions. Binding of HDL to the platelet was saturable, and a class of sites that maximally bound 1,585 +/- 390 HDL particles, with a dissociation constant of 3.1 X 10(-8) mol/L, was identified. Binding of LDL to the platelet was more complex, but evidence for a class of sites that bound 7,075 +/- 4,800 LDL particles, with a dissociation constant of 4 X 10(-8) mol/L, was found. LDL was a poor inhibitor of 125I-HDL binding to the platelet, whereas HDL was an effective inhibitor of 125I-LDL binding. The capacity of HDL to bind or inhibit LDL binding was not dependent on its apoprotein E content. These results are most readily interpreted in terms of two types of lipoprotein interaction sites on platelets: (1) an HDL binding site that does not bind or interacts poorly with LDL, and (2) an LDL binding site that recognizes or is otherwise altered by HDL. The HDL site may be similar to the HDL receptor expressed by steroidogenic tissues in terms of apoprotein specificity. The LDL site is not the same as the LDL receptor of most extrahepatic cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6331546

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Low density lipoprotein causes general cellular activation with increased phosphatidylinositol turnover and lipoprotein catabolism.

Authors:  L H Block; M Knorr; E Vogt; R Locher; W Vetter; P Groscurth; B Y Qiao; D Pometta; R James; M Regenass
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  RNA-mediated regulation of Receptor-Ck gene in human platelets.

Authors:  J Singh; D Kaul
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

3.  Intracellular mechanisms in the activation of human platelets by low-density lipoproteins.

Authors:  H E Andrews; J W Aitken; D G Hassall; V O Skinner; K R Bruckdorfer
Journal:  Biochem J       Date:  1987-03-01       Impact factor: 3.857

4.  Role of platelets in cholesteryl ester formation by U-937 cells.

Authors:  M E Mendelsohn; J Loscalzo
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

5.  New mechanism for foam cell generation in atherosclerotic lesions.

Authors:  L K Curtiss; A S Black; Y Takagi; E F Plow
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

6.  Lipoprotein receptor 'CK'--dependent signalling in human platelets.

Authors:  D Kaul; N Kochhar; J Singh
Journal:  Mol Cell Biochem       Date:  1995-10-18       Impact factor: 3.396

Review 7.  Platelet activation in normo- and hyperlipoproteinemias.

Authors:  J Nimpf; H Wurm; G M Kostner; T Kenner
Journal:  Basic Res Cardiol       Date:  1986 Sep-Oct       Impact factor: 17.165

Review 8.  Scavenger receptor BI: a multi-purpose player in cholesterol and steroid metabolism.

Authors:  Menno Hoekstra; Theo-Jc Van Berkel; Miranda Van Eck
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

Review 9.  Interdependence of pharmacologically-induced and endothelium-mediated coronary vasodilation in antianginal therapy.

Authors:  E Bassenge; D J Stewart
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

10.  Decreased capacity to inhibit platelet hyperactivity and to stabilize prostacyclin of high-density lipoproteins in experimental diabetes.

Authors:  I Ginon; C Talussot; G Ponsin; M Ciavatti
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.